Latest Immunosuppressants Stories
HORSHOLM, Denmark, July 28, 2014 /PRNewswire/ -- Veloxis Pharmaceuticals A/S (OMX: VELO) and Chiesi Farmaceutici S.p.A.
Emerging Therapies, Especially IL-17 Inhibitors, Have Potential Relative to Current Therapies in Improving Psoriatic Plaques, According to Findings from Decision Resources Group BURLINGTON,
Nearly half a million dollars given to early-career physicians to study psoriatic disease PORTLAND, Ore., July 17, 2014 /PRNewswire-USNewswire/ -- Twelve residents and medical students each
Company Advances Development as Part of Collaboration with Baxter International's Biopharmaceutical Business REDWOOD CITY, Calif., July 16, 2014 /PRNewswire/ --
Strengthens Leadership Team with Addition of Experienced Medical Device Executive BOSTON, July 15, 2014 /PRNewswire/ --
- Results of two Phase III psoriasis studies show secukinumab, the first psoriasis IL-17A inhibitor filed with regulatory bodies, met all co-primary and key secondary endpoints
-- Newly Issued US Patent Covers Medical Device Coating Process and Compositions -- DURHAM, N.C., July 9, 2014 /PRNewswire/ -- Micell Technologies, Inc.
Data presented today at the European League Against Rheumatism Annual Congress (EULAR 2014) showed that a significant number of patients with psoriatic arthritis (PsA) were not receiving doses of the tumour necrosis factor-alpha (TNFα) inhibitor adalimumab necessary to achieve optimal clinical benefit.
- Dermira obtains exclusive rights to develop Cimzia® in psoriasis in the US, Canada and the European Union BRUSSELS and REDWOOD CITY, Calif., July 3, 2014 /PRNewswire/ -- UCB, a global biopharmaceutical
- One of a pair of round metal cymbals attached to the fingers and struck together for rhythm and percussion in belly dancing.